NSCLC patients with low CK7 expression (fold < 2) have a long DFS while 92.5% (49/53) patients with high CK7 expression (fold ≥ 2) suffer progression, metastasis, or death. This evidence concerns the gene KRT7 and non-small cell lung carcinoma.